BMY
AI, but make it pharmaceutical
Bristol Myers Squibb is handing Anthropic’s Claude AI model a pretty big companywide role: more than 30,000 employees are getting access as BMS tries to make the drug machine run faster. The goal is straightforward — use AI to help discover, develop, and deliver new medicines without making your scientists do every tedious step the old-fashioned way.
Why investors should care
This isn’t a flashy one-off pilot with a tidy demo and a sad little press release. It’s a broad deployment inside one of the biggest drugmakers out there, which suggests BMS thinks AI can actually shave time off real workflows. If that works, the payoff could show up in faster research cycles, lower operational friction, and maybe a little extra pep in the pipeline.
The bigger picture
Pharma companies have been racing to prove that AI is more than a corporate buzzword they can slap onto a slide deck. Deals like this are basically the industry saying, “Fine, let’s see if the robot can earn its keep.” For BMS, the upside is less about headlines and more about whether Claude helps scientists move from idea to medicine faster.
Big picture: if AI can help shave even a little time and hassle off drug development, that’s the kind of boring win Wall Street actually loves.